Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles

被引:178
作者
Cole, Adam J. [1 ]
David, Allan E. [1 ,3 ]
Wang, Jianxin [1 ,4 ]
Galban, Craig J. [2 ]
Yang, Victor C. [1 ,5 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiol, Ctr Mol Imaging, Sch Med, Ann Arbor, MI 48109 USA
[3] Ind Sci & Technol Network Inc, York, PA 17404 USA
[4] Fudan Univ, Dept Pharmaceut, Sch Pharm, Shanghai 201203, Peoples R China
[5] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300070, Peoples R China
基金
美国国家卫生研究院;
关键词
Magnetic nanoparticles; Magnetic targeting; Polyethylene glycol (PEG); Pharmacokinetics; Drug delivery; Brain tumor; DRUG-DELIVERY; THERAPY; GLIOMA; CHEMOTHERAPY; MRI;
D O I
10.1016/j.biomaterials.2011.05.024
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Magnetic iron oxide nanoparticles (MNPs) have been studied to circumvent the limitations of status-quo brain tumor therapy and can be targeted by applying an external magnetic field to lesions. To address the pharmacokinetic shortcomings of MNPs that can limit targeting efficiency, we recently reported a long-circulating polyethylene glycol modified, cross-linked starch MNP (PEG-MNP) suitable for magnetic targeting. Using a rat model, this work explores the biodistribution patterns of PEG-MNPs in organs of elimination (liver, spleen, lung, and kidney) and shows proof-of-concept that enhanced magnetic brain tumor targeting can be achieved due to the relatively long circulation lifetime of the nanoparticles. Reductions in liver (similar to 12-fold) and spleen (similar to 2.5-fold) PEG-MNP concentrations at 1 h compared to parent starch-coated MNPs (D) confirm plasma pharmacokinetics observed previously. While liver concentrations of PEG-MNPs remained considerably lower than those observed for D at 1 h through 60 h, spleen values continue to increase and are markedly higher at later time points a trend also observed with histology. Limited to no distribution of PEG-MNPs was visualized in lung or kidney throughout the 60 h course evaluated. Enhanced, selective magnetic brain tumor targeting (t = 1 h) of PEG-MNPs (12 mg Fe/kg) was confirmed in 9L-glioma tumors, with up to 1.0% injected dose/g tissue nanoparticle delivery achieved - a 15-fold improvement over targeted D (0.07% injected dose/g tissue). MRI and histological analyses visually confirmed enhanced targeting and also suggest a limited contribution of passive mechanisms to tissue retention of nanoparticles. Our results are exciting and justify both further development of PEG-MNP as a drug delivery platform and concurrent optimization of the magnetic brain tumor targeting strategy utilized. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6291 / 6301
页数:11
相关论文
共 30 条
  • [11] A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo
    David, Allan E.
    Cole, Adam J.
    Chertok, Beata
    Park, Yoon Shin
    Yang, Victor C.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2011, 152 (01) : 67 - 75
  • [12] Magnetic nanoparticles for drug delivery
    Dobson, J
    [J]. DRUG DEVELOPMENT RESEARCH, 2006, 67 (01) : 55 - 60
  • [13] Magnetic nanoparticles for cancer therapy
    Goya, G. F.
    Grazu, V.
    Ibarra, M. R.
    [J]. CURRENT NANOSCIENCE, 2008, 4 (01) : 1 - 16
  • [14] Surface-modified superparamagnetic nanoparticles for drug delivery: Preparation, characterization, and cytotoxicity studies
    Gupta, AK
    Wells, S
    [J]. IEEE TRANSACTIONS ON NANOBIOSCIENCE, 2004, 3 (01) : 66 - 73
  • [15] EGFRvIII Antibody-Conjugated Iron Oxide Nanoparticles for Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery and Targeted Therapy of Glioblastoma
    Hadjipanayis, Costas G.
    Machaidze, Revaz
    Kaluzova, Milota
    Wang, Liya
    Schuette, Albert J.
    Chen, Hongwei
    Wu, Xinying
    Mao, Hui
    [J]. CANCER RESEARCH, 2010, 70 (15) : 6303 - 6312
  • [16] Bioavailability of magnetic nanoparticles to the brain
    Huang, Bor-Ren
    Chen, Pin-Yuan
    Huang, Chiung-Yin
    Jung, Shih-Ming
    Ma, Yunn-Hwa
    Wu, Tony
    Chen, Jyh-Ping
    Wei, Kuo-Chen
    [J]. JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2009, 321 (10) : 1604 - 1609
  • [17] *IHCWORLD, 2010, PRUSS BLUE STAIN PRO
  • [18] Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats
    Jain, Tapan K.
    Reddy, Maram K.
    Morales, Marco A.
    Leslie-Pelecky, Diandra L.
    Labhasetwar, Vinod
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (02) : 316 - 327
  • [19] Targeted therapy for neuro-oncology: reviewing the menu
    Lampson, Lois A.
    [J]. DRUG DISCOVERY TODAY, 2009, 14 (3-4) : 185 - 191
  • [20] Rapid Pharmacokinetic and Biodistribution Studies Using Cholorotoxin-Conjugated Iron Oxide Nanoparticles: A Novel Non-Radioactive Method
    Lee, Michelle Jeung-Eun
    Veiseh, Omid
    Bhattarai, Narayan
    Sun, Conroy
    Hansen, Stacey J.
    Ditzler, Sally
    Knoblaugh, Sue
    Lee, Donghoon
    Ellenbogen, Richard
    Zhang, Miqin
    Olson, James M.
    [J]. PLOS ONE, 2010, 5 (03):